

# Epiomic Epidemiology Series: Sarcopenia Forecast in 13 Major Markets 2016-2026

https://marketpublishers.com/r/E7CD38E4E16EN.html

Date: August 2016 Pages: 50 Price: US\$ 6,382.00 (Single User License) ID: E7CD38E4E16EN

# **Abstracts**

Sarcopenia is defined as the progressive and generalised loss of skeletal muscle as a natural result of the ageing process. Loss of muscle mass tends to start any time after the age of 30, but the accompanying loss of strength increases exponentially with age. Sarcopenia is characterised by atrophy of (predominantly) fast-twitch muscle fibres with accumulation of fat within muscle tissue. It is thought that the Akt pathway, which drives protein turn-over in the muscle, becomes tipped toward net loss of muscle. Higher activation of the Akt pathway and consequently loss of muscle mass with age has been linked with: decrease in testosterone levels, decreased synthetic capacity of muscle ('anabolic resistance'), increased insulin resistance, decreased IGF-1 levels.

Patients with sarcopenia have an increased risk of adverse outcomes such as physical disability, poorer quality of life, hospitalisation and mortality.

This report provides the current prevalent population for Sarcopenia across 13 Major Markets (USA, France, Canada, Germany, Italy, Spain, Brazil, India, UK, Australia, Japan, Korea and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Sarcopenia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Diseases associated with sarcopenia:



Obesity

Type 2 diabetes

Metabolic syndrome and insulin resistance

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global Sarcopenia's market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of Sarcopenia and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on Sarcopenia's prevalent population.

Identify sub-populations within Sarcopenia which require treatment.

Gain an understanding of the specific markets that have the largest number of Sarcopenia patients.



## Contents

Introduction Cause of the Disease **Risk Factors & Prevention** Diagnosis of the Disease Variation by Geography/Ethnicity **Disease Prognosis & Clinical Course** Key Co-morbid Conditions/Features Associated with the Disease Methodology for Quantification of Patient Numbers **Top-Line Prevalence for Sarcopenia** Features of Sarcopenia Patients Sarcopenia by Class Sarcopenic Obesity Abbreviations used in the Report Other Black Swan Analysis Publications Black Swan Analysis Online Patient-Based Databases Patient-Based Offering **Online Pricing Data and Platforms** References Appendix





### **List Of Tables**

#### LIST OF TABLES

Sarcopenia categories by cause Measurements of muscle mass, strength and function in research and practice Criteria for the diagnosis of sarcopenia EWGSOP conceptual stages of sarcopenia Prevalence of Sarcopenia, total (000s) Prevalence of Sarcopenia, males (000s) Prevalence of Sarcopenia, females (000s) Sarcopenia by class, total (000s) Sarcopenic obesity by class, total (000s) Abbreviations and Acronyms used in the report USA Prevalence of Sarcopenia by 5-yr age cohort, males (000s) USA Prevalence of Sarcopenia by 5-yr age cohort, females (000s) France Prevalence of Sarcopenia by 5-yr age cohort, males (000s) France Prevalence of Sarcopenia by 5-yr age cohort, females (000s) Canada Prevalence of Sarcopenia by 5-yr age cohort, males (000s) Canada Prevalence of Sarcopenia by 5-yr age cohort, females (000s) Germany Prevalence of Sarcopenia by 5-yr age cohort, males (000s) Germany Prevalence of Sarcopenia by 5-yr age cohort, females (000s) Italy Prevalence of Sarcopenia by 5-yr age cohort, males (000s) Italy Prevalence of Sarcopenia by 5-yr age cohort, females (000s) Spain Prevalence of Sarcopenia by 5-yr age cohort, males (000s) Spain Prevalence of Sarcopenia by 5-yr age cohort, females (000s) Brazil Prevalence of Sarcopenia by 5-yr age cohort, males (000s) Brazil Prevalence of Sarcopenia by 5-yr age cohort, females (000s) India Prevalence of Sarcopenia by 5-yr age cohort, males (000s) India Prevalence of Sarcopenia by 5-yr age cohort, females (000s) UK Prevalence of Sarcopenia by 5-yr age cohort, males (000s) UK Prevalence of Sarcopenia by 5-yr age cohort, females (000s) Australia Prevalence of Sarcopenia by 5-yr age cohort, males (000s) Australia Prevalence of Sarcopenia by 5-yr age cohort, females (000s) Japan Prevalence of Sarcopenia by 5-yr age cohort, males (000s) Japan Prevalence of Sarcopenia by 5-yr age cohort, females (000s) Korea Prevalence of Sarcopenia by 5-yr age cohort, males (000s) Korea Prevalence of Sarcopenia by 5-yr age cohort, females (000s) China Prevalence of Sarcopenia by 5-yr age cohort, males (000s)



China Prevalence of Sarcopenia by 5-yr age cohort, females (000s)



#### I would like to order

Product name: Epiomic Epidemiology Series: Sarcopenia Forecast in 13 Major Markets 2016-2026 Product link: <u>https://marketpublishers.com/r/E7CD38E4E16EN.html</u>

Price: US\$ 6,382.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

#### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/E7CD38E4E16EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970